RESUMEN
BACKGROUND: Paliperidone palmitate is a long-acting, second-generation antipsychotic (SGA) indicated for the treatment of acute exacerbations and maintenance treatment of adults with schizophrenia. This study addressed the response to paliperidone palmitate in Latin American patients with acute symptoms and recently diagnosed schizophrenia. OBJECTIVE: Explore the efficacy and tolerability of paliperidone palmitate administered once a month for 4 months in patients with acute phase and recent diagnosis (within 1-6 years) of schizophrenia in 3 Latin American countries. METHODS: This was a non-randomized, open-label, multicenter study with paliperidone palmitate injected intramuscularly in the deltoid muscle at an initial loading dose of 150 mg eq. (234 mg) on day 1 and 100 mg eq. (156 mg) on day 8 (± 4 days). The recommended maintenance dose was 75 mg eq. (117 mg) from day 36 to day 92. Efficacy was evaluated with PANSS and CGI-S. The last observation carried forward (LOCF) was used for efficacy analysis for imputation of missing data; no adjustments were made for multiplicity. Adverse events were evaluated during treatment. RESULTS: The patient retention rate was 84.0% (144 patients received study drug; 121 finished the study). The percentage of patients with a reduction of at least 30% in PANSS total score compared to baseline gradually increased during the study, and at the end, 78.4% of patients showed response. The PANSS total score and CGI-S scores decreased significantly from baseline to LOCF endpoint (P <0.0001 for both); significant reduction in PANSS total score was observed at day 8 and persisted to the end of the study. Most common adverse events were muscle rigidity (11.8%), akathisia (11.1%), injection-site pain (7.6%), weight gain (7.6%), and insomnia (7.6%). CONCLUSION: Paliperidone palmitate was efficacious in Latin American patients studied with an acute exacerbation and recent diagnosis of schizophrenia, and no new safety signals were identified.
RESUMEN
Objetivo: Presentar la historia un hombre joven que desde la infancia ha mostrado rasgos de trastorno de personalidad depresiva. Método: Reporte de caso. Resultados y conclusión: Si bien el trastorno de personalidad depresiva tan sólo figura en el anexo del DSM-IV, ha sido ampliamente discutido en diversas publicaciones. En el presente caso clínico, a partir de la narración en primera persona, se emplea una aproximación de tipo fenomenológico que destaca el ámbito de las vivencias predominantes de alguien con este trastorno de personalidad; las principales son el sinsentido de la vida, el aburrimiento y la sensación de vacío.
Objective: To present the story of a young man who has shown depressive personality traits since infancy. Methods: Case report. Results and conclusion: Even though depressive personality disorder is described only in the annex of DSM-IV, it has been widely discussed in various publications. In this clinical case with a first person narration, a phenomenological approach is used that highlights the environment of the predominant experiences of someone with this personality disorder; namely the senselessness of life, boredom and a sensation of emptiness
